Peter J Bostrom
Overview
Explore the profile of Peter J Bostrom including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
153
Citations
1921
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nikulainen I, Salminen A, Hogerman M, Seikkula H, Bostrom P, The Finnish National Cystectomy Database Research Group
Cancers (Basel)
. 2025 Feb;
17(3).
PMID: 39941873
Objectives: To investigate neoadjuvant chemotherapy (NAC) eligibility, utilization, and survival outcomes for muscle-invasive bladder cancer patients undergoing radical cystectomy (RC) in a Finnish population. Materials And Methods: Data from the...
2.
Anttinen M, Makela P, Nurminen P, Parssinen H, Malaspina S, Sainio T, et al.
Eur Urol Open Sci
. 2024 Dec;
71:69-77.
PMID: 39703741
Background And Objective: Toxicity from local salvage therapy for radiorecurrent prostate cancer (PCa) remains a concern. This phase 2 study evaluates the outcomes of salvage magnetic resonance imaging (MRI)-guided transurethral...
3.
Seikkula H, Hyysalo J, Hogerman M, Bostrom P, Ettala O
BJUI Compass
. 2024 Nov;
5(11):1106-1113.
PMID: 39539557
Objectives: To assess the role of ultrasensitive PSA values (usPSA) after radical prostatectomy in predicting the subsequent biochemical recurrence (BCR). Material And Methods: The study included 1836 patients who underwent...
4.
Kettunen K, Mathlin J, Lamminen T, Laiho A, Hakkinen M, Auriola S, et al.
EBioMedicine
. 2024 Sep;
108:105359.
PMID: 39342807
Background: Bladder cancer is a highly over-represented disease in males. The involvement of sex steroids in bladder carcinogenesis and the utilisation of steroid hormone action as a therapeutic target have...
5.
van Gennep E, Claps F, Bostrom P, Shariat S, Neuzillet Y, Zlotta A, et al.
Bladder Cancer
. 2024 Aug;
10(2):119-132.
PMID: 39131875
Background: Prognostic tools in pathological-node (pN) patients after radical cystectomy (RC) are needed. Objectives: To evaluate the prognostic impact of lymph node (LN)-density on disease-specific survival (DSS) in patients with...
6.
Islam M, Dhondt B, Syed P, Khan M, Gidwani K, Webber J, et al.
J Extracell Biol
. 2024 Jun;
1(10):e64.
PMID: 38939212
Urinary extracellular vesicles (uEVs) are enriched with glycosylated proteins which have been extensively studied as putative biomarkers of urological cancers. Here, we characterized the glycosylation and integrin profile of EVs...
7.
Oedorf K, Haug E, Liedberg F, Jarvinen R, Gudjonsson S, Bostrom P, et al.
BMC Urol
. 2024 Jun;
24(1):132.
PMID: 38914985
Background: Upper tract urothelial carcinoma (UTUC) is a rare malignancy, with typically only few new cases annually per urological department. Adherence to European association of urology (EAU) guidelines on UTUC...
8.
Zniber M, Lamminen T, Taimen P, Bostrom P, Huynh T
Heliyon
. 2024 Apr;
10(7):e28949.
PMID: 38617934
Background: Prostate cancer (PCa) and benign prostatic hyperplasia (BPH) are prevalent conditions affecting a significant portion of the male population, particularly with advancing age. Traditional diagnostic methods, such as digital...
9.
Kalinen S, Kallonen T, Gunell M, Ettala O, Jambor I, Knaapila J, et al.
Eur Urol Open Sci
. 2024 Mar;
62:140-150.
PMID: 38500636
Background: Although prostate cancer (PCa) is the most common cancer in men in Western countries, there is significant variability in geographical incidence. This might result from genetic factors, discrepancies in...
10.
Falagario U, Lantz A, Jambor I, Busetto G, Bettocchi C, Finati M, et al.
World J Urol
. 2023 Oct;
41(11):2967-2974.
PMID: 37787941
Purpose: The primary aim of this study was to evaluate if exposure to 5-alpha-reductase inhibitors (5-ARIs) modifies the effect of MRI for the diagnosis of clinically significant Prostate Cancer (csPCa)...